ClinicalTrials.gg
RecruitingNCT05456841Updated Oct 7, 2026

Empathic Communication Skills (ECS) Training

An interventional study of Empathic Communication Skills (ECS) training and Standard of Care participant interaction in Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 12 sites in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.
Updated Oct 1, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,232
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center — 9 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
2nd of 62
1,232 · median 48
Started
2023
with 2 others
No phase
16 of 108
3 open now
Primary completion
2027-08
later than 11 of 19 live
Registered
100th of 108
by date

Among the 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 2nd largest by planned enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2023, is one of 16 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 100th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Lung Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

Research indicates that perceived stigma within medical encounters is prevalent and problematic for lung cancer patients' well-being and quality of cancer care. Promoting empathic communication appears to be a potentially effective intervention target to help reduce patients' perceptions of stigma within clinical encounters; however, no formal trainings exist that focus on teaching empathic communication to oncology care providers (OCPs). Building upon favorable findings from a prior R21 (R21CA202793) and the importance of developing interventions to address lung cancer stigma, our goal is to conduct a national trial of empathic communication skills (ECS) training to facilitate improvements in the medical and psychosocial care of patients through de-stigmatizing interactions with OCPs for patients diagnosed with lung cancer.

Read the detailed description

The aims of this study are:

  1. to evaluate the effect of the ECS training on OCP primary outcomes (communication and empathic skill uptake) and secondary outcomes (ECS training appraisal - relevance, novelty, clarity; self-efficacy, empathy, compassion burn-out);
  2. to evaluate the effect of the ECS training vs. WLC on patients' reported primary outcomes (lung cancer stigma), and secondary outcomes (perceived clinician empathy, satisfaction with communication, psychological distress, patients' experience of clinical encounter, and overall patient satisfaction).

    Additionally, acceptance of referral to tobacco cessation (for those currently smoking) will be explored; and

  3. to examine potential moderators of OCP (e.g., demographic characteristics, professional role characteristics) and patient outcomes (e.g., demographic characteristics, illness characteristics).

Our central hypothesis is that the ECS training will demonstrate significant short-term improvements in clinicians' uptake of empathic skills and self-efficacy and will be superior to WLC with regards to patient reported measures of stigma, clinician empathy, satisfaction, and overall experience.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • lung cancer
  • thoracic oncology physician
  • thoracic oncology nurse practitioner
  • thoracic oncology physicians assistant
  • 21-339
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Site Eligibility

  • Employs at least 15 FTE OCPs (i.e., oncologists, nurse practitioners and physician assistants) as per self report
  • Reports a clinic volume of at least 20 new lung cancer patients per month as per self report

OCP Participant Eligibility

  • OCPs who are thoracic oncology physicians (radiologists, medical oncologists, pulmonologists, and surgeons), NPs, or PAs and currently treating lung cancer patients, as per self-report;
  • OCP conducts consultations with lung cancer patients, as per self-report;
  • OCP sees at least 1 lung cancer patient per week, as per self-report;

Patient Eligibility

  • Patient under the care of a participating OCP as per self report;
  • English and/or Spanish speaking;

    • In general, which language do you prefer to receive your medical care, English/Spanish/both English and Spanish Equally?
    • If English, treat as fluent in English, no additional language questions
    • If Spanish, treat as fluent in Spanish, no additional language questions
    • If both English and Spanish equally, ask the follow-up questions and go with whichever language is endorsed as best. If endorsed equally, assign to category patient prefers
    • How well do you speak English? Not at all/ Not well/Well/Very well
    • How well do you speak Spanish? Not at all/Not well/Well/Very well
  • Is at least 18 years of age as per self report;
  • Has a history of suspicious lung mass or confirmed lung cancer diagnosis, as per clinician judgment or medical record note;
  • Is a former or current smoking as per self report;
  • Has had no more than 10 prior visits with the participating OCP, as per the medical record and/or self report

Exclusion criteria

Exclusion Criteria:

Patient Exclusion

  • Individuals of impaired decision-making capacity as per a clinician's judgment or as documented in the EMR.

Site and OCP Exclusion

  • None
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
1,232 participants (estimated)

Study arms

  • Experimental
    Oncology Care Providers/OCP-intervention group

    Providers participate in Empathic Communication Skills (ECS) training

    Behavioral: Empathic Communication Skills (ECS) training

  • Active comparator
    Oncology Care Providers/OCP-control group

    Providers complete all study measures and are offered ECS training after data collection is completed at their site.

    Other: Standard of Care participant interaction

  • Experimental
    Participants with Lung Cancer-intervention group

    Participants will engage with oncology care providers/OCP who have undergone Empathic Communication Skills (ECS) training

    Behavioral: Empathic Communication Skills (ECS) training

  • Active comparator
    Participants with Lung Cancer-control group

    Waitlist control group - WLC

    Other: Standard of Care participant interaction

Interventions

  • BehavioralEmpathic Communication Skills (ECS) training

    The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given "small doses" of an opposing viewpoint (termed as "preparing patients for recurring smoking questions") and suggestions of "counterarguments" in order to make them resistant to future stigmatizing attacks by others

  • OtherStandard of Care participant interaction

    Standard of Care participant interaction

06

What researchers measure

Primary outcomes

  1. Uptake of communication skills using standardized patient assessment/SPAs

    A SPA involves a 12-minute video recorded interaction between the Oncology Care Provider/OCP and the Standardized Patient/SP on a given clinical scenario, using standardized scripts by the SP. Each OCP will participate in one SPA prior to their ECS training and one SPA following training or the timed control period. In contrast to clinical consultation recordings with varied clinical situations that do not necessitate the use of all strategies and skills, the semi-structured nature of SPAs permits appraisal of all desired elements of training.

    Time frame: 3 months

  2. Uptake of empathy skills using standardized patient assessment/SPAs

    A SPA involves a 12-minute video recorded interaction between the Oncology Care Provider/OCP and the Standardized Patient/SP on a given clinical scenario, using standardized scripts by the SP. Each OCP will participate in one SPA prior to their ECS training and one SPA following training or the timed control period. In contrast to clinical consultation recordings with varied clinical situations that do not necessitate the use of all strategies and skills, the semi-structured nature of SPAs permits appraisal of all desired elements of training.

    Time frame: 3 months

07

Study locations

8 of 12 sites recruiting
  • Providence St. Joseph Health (Data Collection Only)
    Irvine, California 92612, United States
    Completed

    Not enrolling at this site.

  • BAPTIST ALLIANCE - MCI (Data Collection Only)
    Miami, Florida 33143, United States
    Recruiting
    • Ian Bostock, MD · Contact786-596-2000
  • Advocate Health Care Network
    Libertyville, Illinois 60048, United States
    Recruiting
    • Michael Breen, MD · Contact847-367-6781
  • University of Kentucky (Data Collection Only)
    Lexington, Kentucky 40536-0093, United States
    Completed

    Not enrolling at this site.

  • Munson Healthcare (Data Collection Only)
    Traverse City, Michigan 49684, United States
    Completed

    Not enrolling at this site.

  • Hackensack Meridian Health (Data collection only)
    Hackensack, New Jersey 07601, United States
    Recruiting
    • David Greenberg, MD · Contact551-996-8704
  • Roswell Park Cancer Institute (Data Collection Only)
    Buffalo, New York 14263-0001, United States
    Recruiting
    • Elisabeth Dexter, MD · Contact716-845-2300
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Smita Banerjee, PhD · Contact646-888-0011
  • Virtua Health (Data Collection Only)
    Philadelphia, Pennsylvania 08060, United States
    Completed

    Not enrolling at this site.

  • University of Pennsylvania (Data Collection Only)
    Philadelphia, Pennsylvania 19104-4283, United States
    Recruiting
    • Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP · Contact(215) 615-5858
  • Fox Chase Cancer Center (Data Collection Only)
    Philadelphia, Pennsylvania 19111, United States
    Recruiting
    • Linda Fleisher, PhD, MPH · Contact215-728-4066
  • Chesapeake Regional Healthcare (Data Collection Only)
    Chesapeake, Virginia 23320, United States
    Recruiting
    • Stephen Noble, MD · Contact757-842-4499
08

References and documents

Publications

  • Banerjee SC, Malling CD, Schofield EA, Carter-Bawa L, Bylund CL, Hamann HA, Parker PA, Shen MJ, Studts JL, Williamson TJ, Ostroff JS. Empathic communication skills training to reduce lung cancer stigma: Study protocol of a cluster randomized control trial. Contemp Clin Trials. 2024 Oct;145:107669. doi: 10.1016/j.cct.2024.107669. Epub 2024 Aug 23. PubMed 39182827 ↗
  • Banerjee SC, Malling CD, Shen MJ, Williamson TJ, Bylund CL, Studts JL, Mullett T, Carter-Bawa L, Hamann HA, Parker PA, Steliga M, Feldman J, Pantelas J, Borondy-Kitts A, Rigney M, King JC, Fathi JT, Rosenthal LS, Smith RA, Ostroff JS. Getting ready for prime time: Recommended adaptations of an Empathic Communication Skills training intervention to reduce lung cancer stigma for a national multi-center trial. Transl Behav Med. 2023 Sep 28;13(10):804-808. doi: 10.1093/tbm/ibad048. PubMed 37579304 ↗

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Aug 2027, 52 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 52 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Aug 2026 → Aug 2027 and completion Aug 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2022
First posted
Jul 13, 2022
StartActual
Apr 28, 2023
Primary completionEst.
Aug 31, 2027was Aug 2026
CompletionEst.
Aug 31, 2027was Aug 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Aug 31, 2027
Oct 1, 2026
Study completion
Aug 31, 2026→Aug 31, 2027
Oct 1, 2026
Show all 2 updates
  1. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 1, 2026
    Primary completion Aug 31, 2026→Aug 31, 2027
    Study completion Aug 31, 2026→Aug 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05456841
Collaborators
American Cancer Society, Inc., Go2 Foundation for Lung Cancer
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
Apr 28, 2023
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Smita Banerjee, PhD
Contact
banerjes@mskcc.org
646-888-0011
Jamie Ostroff, PhD
Contact
ostroffj@mskcc.org
646-888-0041
Smita Banerjee, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion